The goal of this study is to create a digital platform for managing patients with chronic heart failure, those with long-term ventricular assistance, or heart transplant recipients. This platform aims to help doctors make clinical decisions and change treatments based on continuous monitoring and the collection of medical, clinical, physiological, behavioral, psychosocial, and real-world data from these patients. The ultimate goal is to reduce mortality and hospitalization rates for this group of patients while improving their quality of life, safety, and well-being. To do this, participants will be divided into two groups: * Intervention Group: The data collected by the platform will be available to their treating doctors. * Control Group: Doctors will not have access to the data. All participating patients will receive a set of devices and sensors to collect data such as vital signs, physical activity, sleep quality, psychological and nutritional status, and environmental data. All this information will be gathered through a mobile app designed for the study. The follow-up will last for 18 months, during which there will be 4 in-person medical visits (spaced 4 months apart). Participation in the study won't affect patients' scheduled medical visits related to their illness or their usual treatment.
Specifically, the devices that will be given to the patients and their required use will be as follows: A Smartphone: This will have the app with the platform designed for the study. The patient must interact with it daily to enter data. A Blood Pressure Monitor: The patient will need to take their blood pressure every day and send it via Bluetooth to the mobile platform (the connection setup will be done by the study team before giving it to the patients). An Oxygen Saturation Monitor: The patient will need to check their oxygen levels daily and send the data via Bluetooth to the mobile platform (the connection setup will be done by the study team before giving it to the patients). A Scale: The patient will need to weigh themselves daily and transmit the data via Bluetooth to the mobile platform (the connection setup will be done by the study team before giving it to the patients). A Smartwatch: The patient must send data on their physical activity and sleep daily via Bluetooth to the mobile platform (the connection setup will be done by the study team before giving it to the patients). Home Humidity and Temperature Sensors and a Home Gateway Device (Raspberry Pi): The patient will need to connect this last device to their home internet network. The connection setup will be done by the study team before giving it to the patients. There are other data and information that the patient must manually enter into the app, such as daily body temperature, symptoms they experience (like increased fatigue or shortness of breath), or data on the functioning of the long-term ventricular assistance (controller parameters or alarm presence). Additionally, the app will show the patient's current medication, which they need to confirm they have taken correctly. The scheduled visits during the study will take place at the Baseline and every four months. These visits will include an in-person medical visit, an electrocardiogram, a blood test, and a 6-minute walk test. Also, at each visit, a series of questionnaires will be given to assess the patient's cognitive, nutritional, and psychological state, as well as their quality of life and that of their primary caregivers. Some visits will also include more specific cardiac tests, like an echocardiogram or a cardiopulmonary exercise test. If during the study follow-up, the treating doctors unexpectedly discover any information that affects the patient's health or quality of life, the patient will be informed immediately, even if it is unrelated to the study's purpose. All data recorded throughout the study will be stored anonymously by the study platform.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Enrollment
390
data collected by the devices will be reviewed by the treating physician in the intervention group
Patients in the control group will be monitored but the information will not be available for the clinicians nor the artificial intelligence recommendations
Medizinische Hochschule Hannover ('Mhh')
Hanover, Germany
National and Kapodistrian University of Athens
Athens, Greece
Onassis Cardiac Surgery Center
Athens, Greece
Alma Mater Studiorum - Universita Di Bologna
Bologna, Italy
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain
Hospital Universitario Ramón Y Cajal
Madrid, Spain
Difference in days lost due to unplanned cardiovascular hospitalizations or all-cause death between groups
Comparison of days lost due to unplanned cardiovascular hospitalizations or all-cause death between groups
Time frame: From the enrollment to the end of the follow up (18 months)
Differences in the rates of occurrence of death or unplanned hospitalization/ambulatory administration of intravenous (iv) diuretics, iv antibiotics or iv steroids
Comparison of the rates of the occurrence of death or unplanned hospitalization/ambulatory administration of intravenous (iv) diuretics, iv antibiotics or iv steroids between groups
Time frame: From the enrollment to the end of the follow up (18 months)
Rates of all-cause mortality
Time frame: From the enrollment to the end of the follow up (18 months)
Rates of cardiovascular mortality
Time frame: From the enrollment to the end of the follow up (18 months)]
Differences in time to first unplanned HF hospitalization
Time frame: From the enrollment to the end of the follow up (18 months)]
Differences in time to first unplanned cardiovascular hospitalization
Time frame: From the enrollment to the end of the follow up (18 months)]
Rate of total unplanned HF hospitalizations
Time frame: From the enrollment to the end of the follow up (18 months)
Rate of total unplanned cardiovascular hospitalizations
Time frame: From the enrollment to the end of the follow up (18 months)
Differences in days lost due to HF hospitalizations
Time frame: From the enrollment to the end of the follow up (18 months)]
Differences in the number of Smart device alarm notifications
Time frame: From the enrollment to the end of the follow up (18 months)
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score
between Baseline and last visit. KCCQ ranges from 0 to 100, higher scores indicating higher quality of life
Time frame: From the enrollment to the end of the follow up (18 months)
Change in the levels of NT-proBNP
Between Baseline and last visit
Time frame: From the enrollment to the end of the follow up (18 months)
Change in the Depression Score Patient Health Questionnaire 9 (PHQ-9)
Between baseline and last visit
Time frame: From the enrollment to the end of the follow up (18 months)
Change in the Heart Failure Caregiver Questionnaire (HF-CQ version 5.0)
Between baseline and last visit
Time frame: From the enrollment to the end of the follow up (18 months)]
Difference in the rate of rejection needing treatment in heart transplant patients
Time frame: From the enrollment to the end of the follow up (18 months)
Driveline infection needing antibiotic in left ventricular assist device (LVAD) patients
Time frame: From the enrollment to the end of the follow up (18 months)
Differences in the rate of unplanned visit for heart failure requiring intravenous diuretics
Time frame: From the enrollment to the end of the follow up (18 months)
Difference in the number of visits outside the protocol
Time frame: From the enrollment to the end of the follow up (18 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.